PL1912949T3 - Pochodne cykloheksyloaminoizochinolonu jako inhibitory kinazy RHO - Google Patents

Pochodne cykloheksyloaminoizochinolonu jako inhibitory kinazy RHO

Info

Publication number: PL1912949T3
Authority: PL; Poland
Prior art keywords: cyclohexylamin; rho; kinase inhibitors; isoquinolone derivatives; isoquinolone
Prior art date: 2005-07-26

Application number

PL06776307T

Other languages

English (en)

Inventor

Oliver Plettenburg

Armin Hofmeister

Dieter Kadereit

Joachim Brendel

Matthias Loehn

Original Assignee

Sanofi Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-07-26

Filing date

2006-07-20

Publication date

2012-01-31

2006-07-20 Application filed by Sanofi Sa filed Critical Sanofi Sa

2012-01-31 Publication of PL1912949T3 publication Critical patent/PL1912949T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Neurology (AREA)
Pulmonology (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Reproductive Health (AREA)
Obesity (AREA)
Gynecology & Obstetrics (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
AIDS & HIV (AREA)
Psychiatry (AREA)

PL06776307T 2005-07-26 2006-07-20 Pochodne cykloheksyloaminoizochinolonu jako inhibitory kinazy RHO PL1912949T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP05016153		2005-07-26
EP06776307A EP1912949B1 (en)	2005-07-26	2006-07-20	Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors
PCT/EP2006/007140 WO2007012422A1 (en)	2005-07-26	2006-07-20	Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors

Publications (1)

Publication Number	Publication Date
PL1912949T3 true PL1912949T3 (pl)	2012-01-31

Family

ID=35115842

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL06776307T PL1912949T3 (pl)	2005-07-26	2006-07-20	Pochodne cykloheksyloaminoizochinolonu jako inhibitory kinazy RHO

Country Status (37)

Country	Link
US (2)	US8609691B2 (pl)
EP (1)	EP1912949B1 (pl)
JP (1)	JP5049970B2 (pl)
KR (1)	KR101336678B1 (pl)
CN (1)	CN101228132B (pl)
AR (1)	AR057082A1 (pl)
AT (1)	ATE521595T1 (pl)
AU (1)	AU2006274246B2 (pl)
BR (1)	BRPI0614063A2 (pl)
CA (1)	CA2615663C (pl)
CR (1)	CR9604A (pl)
CY (1)	CY1112085T1 (pl)
DK (1)	DK1912949T3 (pl)
DO (1)	DOP2006000177A (pl)
EC (1)	ECSP088136A (pl)
ES (1)	ES2372067T3 (pl)
GT (1)	GT200600327A (pl)
HK (1)	HK1123036A1 (pl)
HN (1)	HN2008000130A (pl)
HR (1)	HRP20110839T1 (pl)
IL (1)	IL188949A (pl)
MA (1)	MA29639B1 (pl)
MX (1)	MX2008000956A (pl)
MY (1)	MY146644A (pl)
NI (1)	NI200800024A (pl)
NO (1)	NO20080965L (pl)
NZ (1)	NZ565669A (pl)
PE (1)	PE20070181A1 (pl)
PL (1)	PL1912949T3 (pl)
PT (1)	PT1912949E (pl)
RS (1)	RS52241B (pl)
RU (1)	RU2440988C2 (pl)
SI (1)	SI1912949T1 (pl)
TN (1)	TNSN08038A1 (pl)
TW (1)	TWI412521B (pl)
WO (1)	WO2007012422A1 (pl)
ZA (1)	ZA200710952B (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2006264043B2 (en)	2005-06-28	2012-04-26	Sanofi-Aventis	Isoquinoline derivatives as inhibitors of Rho-kinase
SI1912949T1 (sl)	2005-07-26	2011-12-30	Sanofi Sa	Cikloheksilamin izokinolonski derivati kot inhibitorji Rho-kinaze
NI200800025A (es)	2005-07-26	2009-03-03		Derivados de isoquinolona sustituidos con piperidinilo en calidad de inhibidores de rho-quinasa
US7893088B2 (en)	2006-08-18	2011-02-22	N.V. Organon	6-substituted isoquinoline derivatives
CA2663193A1 (en) *	2006-09-11	2008-03-20	N.V. Organon	2-(1-oxo-1h-isoquinolin-2-yl)acetamide derivatives
EP2132194B1 (en)	2006-12-27	2011-03-16	Sanofi-Aventis	Substituted isoquinolines and their use as rho-kinase inhibitors
MY151953A (en) *	2006-12-27	2014-07-31	Sanofi Aventis	Cycloalkylamine substituted isoquinoline derivatives
NZ577984A (en)	2006-12-27	2011-03-31	Sanofi Aventis	Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives
AU2007338406B2 (en)	2006-12-27	2012-08-09	Sanofi-Aventis	Substituted isoquinoline and isoquinolinone derivatives as inhibitors of Rho-kinase
WO2008077551A1 (en)	2006-12-27	2008-07-03	Sanofi-Aventis	Cycloalkylamine substituted isoquinolone derivatives
EP2114920A1 (en)	2006-12-27	2009-11-11	Sanofi-Aventis	Substituted isoquinoline and isoquinolinone derivatives
TW200845988A (en)	2007-04-05	2008-12-01	Astrazeneca Ab	New compounds and their uses 707
RU2010120671A (ru) *	2007-10-24	2011-11-27	Мерк Шарп Энд Домэ Корп. (Us)	Гетероциклические фениламидные антагонисты кальциевых каналов т-типа
EP2303846B1 (en)	2008-06-24	2015-04-29	Sanofi	Substituted isoquinolines and isoquinolinones as rho kinase inhibitors
AU2009262509B2 (en) *	2008-06-24	2014-01-30	Sanofi	Bi-and polycyclic substituted isoquinoline and isoquinoline derivatives as Rho kinase inhibitors
SI2313374T1 (sl) *	2008-06-24	2013-12-31	Sanofi	6-substituirani izokinolini in izokinolinoni
EA018721B1 (ru) *	2008-08-25	2013-10-30	Айрм Ллк	Модуляторы сигнального пути hedgehog
AR073711A1 (es)	2008-10-01	2010-11-24	Astrazeneca Ab	Derivados de isoquinolina
EA033220B1 (ru) *	2013-01-18	2019-09-30	Бристол-Майерс Сквибб Компани	Фталазиноны и изохинолиноны в качестве ингибиторов rock
PE20180248A1 (es)	2013-10-18	2018-02-02	Celgene Quanticel Res Inc	Inhibidores de bromodominio
CN105829285A (zh)	2013-10-23	2016-08-03	中外制药株式会社	喹唑啉酮和异喹啉酮衍生物
FR3017868A1 (fr)	2014-02-21	2015-08-28	Servier Lab	Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN105085478B (zh) *	2014-04-28	2019-04-12	南京明德新药研发股份有限公司	异喹啉磺胺衍生物及其药物组合物和制药用途
AR104259A1 (es)	2015-04-15	2017-07-05	Celgene Quanticel Res Inc	Inhibidores de bromodominio
EP3294871A1 (en)	2015-05-12	2018-03-21	Platod	Combination of pharmacological and microfluidic features for improved platelets production
US9957267B2 (en)	2015-07-01	2018-05-01	Crinetics Pharmaceuticals, Inc.	Somatostatin modulators and uses thereof
EP3445750A4 (en)	2016-04-18	2019-11-27	Celgene Quanticel Research, Inc.	THERAPEUTIC COMPOUNDS
US10150754B2 (en)	2016-04-19	2018-12-11	Celgene Quanticel Research, Inc.	Histone demethylase inhibitors
WO2019023278A1 (en)	2017-07-25	2019-01-31	Crinetics Pharmaceuticals, Inc.	MODULATORS OF SOMATOSTATIN AND USES THEREOF
CN112839647A (zh) *	2018-06-07	2021-05-25	达萨玛治疗公司	Sarm1抑制剂
CN114874236B (zh) *	2022-06-24	2023-05-05	中国工程物理研究院化工材料研究所	一种五元氮杂稠环骨架及其制备方法

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2485537B2 (fr)	1977-04-13	1986-05-16	Anvar	Dipyrido(4,3-b)(3,4-f)indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant
EP0541559A1 (en)	1990-07-31	1993-05-19	E.I. Du Pont De Nemours And Company	Catalytic equilibration of selected halocarbons
US5480883A (en) *	1991-05-10	1996-01-02	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9516709D0 (en)	1995-08-15	1995-10-18	Zeneca Ltd	Medicament
ZA9610741B (en)	1995-12-22	1997-06-24	Warner Lambert Co	4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ES2286834T5 (es)	1996-08-12	2011-01-31	Mitsubishi Tanabe Pharma Corporation	Medicamentos que comprenden un inhibidor de la rho quinasa.
JPH1087629A (ja)	1996-09-18	1998-04-07	Fujisawa Pharmaceut Co Ltd	新規イソキノリン誘導体、およびその医薬用途
EP1007525A1 (en)	1997-08-29	2000-06-14	Zeneca Limited	Aminometyl oxooxazolidinyl benzene derivatives
TW575567B (en)	1998-10-23	2004-02-11	Akzo Nobel Nv	Serine protease inhibitor
US6541456B1 (en)	1999-12-01	2003-04-01	Isis Pharmaceuticals, Inc.	Antimicrobial 2-deoxystreptamine compounds
CA2398388A1 (en) *	2000-01-20	2001-07-26	Koji Kato	Novel piperidine compound and pharmaceutical thereof
US7217722B2 (en)	2000-02-01	2007-05-15	Kirin Beer Kabushiki Kaisha	Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
AU2001239947A1 (en)	2000-02-29	2001-09-12	Curis, Inc.	Methods and compositions for regulating adipocytes
GB0004887D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
AR033517A1 (es)	2000-04-08	2003-12-26	Astrazeneca Ab	Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
GB0013060D0 (en)	2000-05-31	2000-07-19	Astrazeneca Ab	Chemical compounds
AU2001296008A1 (en)	2000-10-27	2002-05-06	Takeda Chemical Industries Ltd.	Process for preparing substituted aromatic compounds and intermediates therefor
EP1351936A1 (en)	2001-01-15	2003-10-15	Glaxo Group Limited	Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
SE0101038D0 (sv)	2001-03-23	2001-03-23	Astrazeneca Ab	Novel compounds
US20030095958A1 (en)	2001-04-27	2003-05-22	Bhisetti Govinda R.	Inhibitors of bace
EP1403255A4 (en) *	2001-06-12	2005-04-06	Sumitomo Pharma	RHO KINASE INHIBITORS
GB0117899D0 (en)	2001-07-23	2001-09-12	Astrazeneca Ab	Chemical compounds
WO2003024450A1 (en)	2001-09-20	2003-03-27	Eisai Co., Ltd.	Methods for treating prion diseases
SE0104340D0 (sv)	2001-12-20	2001-12-20	Astrazeneca Ab	New compounds
CA2493230A1 (en) *	2002-07-22	2004-01-29	Asahi Kasei Pharma Corporation	5-substituted isoquinoline derivative
KR20050019918A (ko) *	2002-07-22	2005-03-03	아사히 가세이 파마 가부시키가이샤	5-치환 이소퀴놀린 유도체
JPWO2004024717A1 (ja)	2002-09-12	2006-01-05	麒麟麦酒株式会社	キナーゼ阻害活性を有するイソキノリン誘導体およびそれを含む医薬
EP1603566B1 (en) *	2003-03-11	2009-01-21	Novartis AG	Use of isoquinoline derivatives for treating cancer and map kinase related diseases
US20040225116A1 (en)	2003-05-08	2004-11-11	Payne Mark S.	Nucleic acid fragments encoding nitrile hydratase and amidase enzymes from comamonas testosteroni 5-MGAM-4D and recombinant organisms expressing those enzymes useful for the production of amides and acids
WO2004105757A2 (en)	2003-05-29	2004-12-09	Schering Aktiengesellschaft	Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
WO2004113297A2 (en)	2003-06-24	2004-12-29	Neurosearch A/S	Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
EP1678623B1 (en)	2003-08-22	2008-10-22	4Links Limited	Communication system using embedded synchronisation
WO2005030791A2 (en)	2003-09-23	2005-04-07	Merck & Co., Inc.	Isoquinolinone potassium channel inhibitors
JP4794446B2 (ja)	2003-09-23	2011-10-19	メルク・シャープ・エンド・ドーム・コーポレイション	イソキノリン系カリウムチャンネル阻害薬
US20050067037A1 (en)	2003-09-30	2005-03-31	Conocophillips Company	Collapse resistant composite riser
US20070060595A1 (en) *	2003-10-10	2007-03-15	Toshio Yoshizawa	Novel fused heterocyclic compound and use thereof
US7449477B2 (en)	2003-11-25	2008-11-11	Eli Lilly And Company	7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B)
WO2005074535A2 (en)	2004-01-30	2005-08-18	Eisai Co., Ltd.	Cholinesterase inhibitors for spinal cord disorders
US20080312189A1 (en)	2004-03-05	2008-12-18	Eisai Co., Ltd.	Cadasil Treatment with Cholinesterase Inhibitors
SE0400850D0 (sv)	2004-03-30	2004-03-31	Astrazeneca Ab	Novel Compounds
JP4969049B2 (ja) *	2004-04-06	2012-07-04	株式会社アマダ	曲げ加工装置
US7517991B2 (en) *	2004-10-12	2009-04-14	Bristol-Myers Squibb Company	N-sulfonylpiperidine cannabinoid receptor 1 antagonists
EP1741525A1 (de)	2005-07-06	2007-01-10	Trumpf Werkzeugmaschinen GmbH + Co. KG	Vorrichtung zur Aufnahme von plattenförmigen Materialien
NI200800025A (es)	2005-07-26	2009-03-03		Derivados de isoquinolona sustituidos con piperidinilo en calidad de inhibidores de rho-quinasa
SI1912949T1 (sl)	2005-07-26	2011-12-30	Sanofi Sa	Cikloheksilamin izokinolonski derivati kot inhibitorji Rho-kinaze
TW200745101A (en)	2005-09-30	2007-12-16	Organon Nv	9-Azabicyclo[3.3.1]nonane derivatives
JP4033221B2 (ja)	2005-12-02	2008-01-16	ダイキン工業株式会社	冷媒加熱装置
US7618985B2 (en)	2005-12-08	2009-11-17	N.V. Organon	Isoquinoline derivatives
TW200738682A (en)	2005-12-08	2007-10-16	Organon Nv	Isoquinoline derivatives
US7893088B2 (en) *	2006-08-18	2011-02-22	N.V. Organon	6-substituted isoquinoline derivatives
NZ577984A (en)	2006-12-27	2011-03-31	Sanofi Aventis	Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives
EP2132194B1 (en)	2006-12-27	2011-03-16	Sanofi-Aventis	Substituted isoquinolines and their use as rho-kinase inhibitors

2006
- 2006-07-20 SI SI200631175T patent/SI1912949T1/sl unknown
- 2006-07-20 BR BRPI0614063-7A patent/BRPI0614063A2/pt active Search and Examination
- 2006-07-20 RS RS20110494A patent/RS52241B/en unknown
- 2006-07-20 ES ES06776307T patent/ES2372067T3/es active Active
- 2006-07-20 AT AT06776307T patent/ATE521595T1/de active
- 2006-07-20 DK DK06776307.8T patent/DK1912949T3/da active
- 2006-07-20 JP JP2008523189A patent/JP5049970B2/ja not_active Expired - Fee Related
- 2006-07-20 EP EP06776307A patent/EP1912949B1/en active Active
- 2006-07-20 KR KR1020087002147A patent/KR101336678B1/ko not_active IP Right Cessation
- 2006-07-20 NZ NZ565669A patent/NZ565669A/en not_active IP Right Cessation
- 2006-07-20 WO PCT/EP2006/007140 patent/WO2007012422A1/en active Application Filing
- 2006-07-20 CN CN2006800271401A patent/CN101228132B/zh not_active Expired - Fee Related
- 2006-07-20 PT PT06776307T patent/PT1912949E/pt unknown
- 2006-07-20 RU RU2008106926/04A patent/RU2440988C2/ru not_active IP Right Cessation
- 2006-07-20 NI NI200800024A patent/NI200800024A/es unknown
- 2006-07-20 PL PL06776307T patent/PL1912949T3/pl unknown
- 2006-07-20 CA CA2615663A patent/CA2615663C/en not_active Expired - Fee Related
- 2006-07-20 AU AU2006274246A patent/AU2006274246B2/en not_active Ceased
- 2006-07-20 MX MX2008000956A patent/MX2008000956A/es active IP Right Grant
- 2006-07-24 MY MYPI20063516A patent/MY146644A/en unknown
- 2006-07-24 TW TW095126883A patent/TWI412521B/zh not_active IP Right Cessation
- 2006-07-24 GT GT200600327A patent/GT200600327A/es unknown
- 2006-07-25 PE PE2006000895A patent/PE20070181A1/es not_active Application Discontinuation
- 2006-07-25 DO DO2006000177A patent/DOP2006000177A/es unknown
- 2006-07-25 AR ARP060103200A patent/AR057082A1/es unknown
2007
- 2007-12-18 ZA ZA200710952A patent/ZA200710952B/xx unknown
- 2007-12-18 CR CR9604A patent/CR9604A/es not_active Application Discontinuation
2008
- 2008-01-21 MA MA30586A patent/MA29639B1/fr unknown
- 2008-01-22 IL IL188949A patent/IL188949A/en not_active IP Right Cessation
- 2008-01-25 TN TNP2008000038A patent/TNSN08038A1/en unknown
- 2008-01-25 EC EC2008008136A patent/ECSP088136A/es unknown
- 2008-01-25 US US12/019,799 patent/US8609691B2/en not_active Expired - Fee Related
- 2008-01-28 HN HN2008000130A patent/HN2008000130A/es unknown
- 2008-02-22 NO NO20080965A patent/NO20080965L/no not_active Application Discontinuation
- 2008-12-29 HK HK08114022.5A patent/HK1123036A1/xx not_active IP Right Cessation
2011
- 2011-06-15 US US13/161,003 patent/US8796458B2/en not_active Expired - Fee Related
- 2011-11-14 HR HR20110839T patent/HRP20110839T1/hr unknown
- 2011-11-24 CY CY20111101153T patent/CY1112085T1/el unknown

Also Published As

Publication number	Publication date
PT1912949E (pt)	2011-11-23
RS52241B (en)	2012-10-31
PE20070181A1 (es)	2007-03-07
RU2440988C2 (ru)	2012-01-27
IL188949A (en)	2013-11-28
AU2006274246B2 (en)	2012-07-12
MY146644A (en)	2012-09-14
SI1912949T1 (sl)	2011-12-30
US8609691B2 (en)	2013-12-17
US8796458B2 (en)	2014-08-05
NO20080965L (no)	2008-02-22
ATE521595T1 (de)	2011-09-15
AU2006274246A1 (en)	2007-02-01
US20110251226A1 (en)	2011-10-13
JP5049970B2 (ja)	2012-10-17
CA2615663A1 (en)	2007-02-01
ZA200710952B (en)	2008-11-26
EP1912949A1 (en)	2008-04-23
KR20080028970A (ko)	2008-04-02
WO2007012422A1 (en)	2007-02-01
CY1112085T1 (el)	2015-11-04
AR057082A1 (es)	2007-11-14
CN101228132B (zh)	2012-10-10
HK1123036A1 (en)	2009-06-05
NZ565669A (en)	2010-05-28
TW200800906A (en)	2008-01-01
TWI412521B (zh)	2013-10-21
JP2009502830A (ja)	2009-01-29
EP1912949B1 (en)	2011-08-24
CR9604A (es)	2008-04-10
CA2615663C (en)	2013-10-15
TNSN08038A1 (en)	2009-07-14
HRP20110839T1 (hr)	2011-12-31
MA29639B1 (fr)	2008-07-01
IL188949A0 (en)	2008-04-13
US20080242699A1 (en)	2008-10-02
MX2008000956A (es)	2008-03-27
DK1912949T3 (da)	2011-11-28
DOP2006000177A (es)	2007-06-15
GT200600327A (es)	2007-02-05
ES2372067T3 (es)	2012-01-13
HN2008000130A (es)	2010-12-27
KR101336678B1 (ko)	2013-12-04
RU2008106926A (ru)	2009-09-10
ECSP088136A (es)	2008-02-20
BRPI0614063A2 (pt)	2011-03-09
CN101228132A (zh)	2008-07-23
NI200800024A (es)	2009-03-03

Publication	Publication Date	Title
IL188702A0 (en)	2008-08-07	Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors
IL188949A0 (en)	2008-04-13	Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors
ZA200710001B (en)	2008-11-26	Isoquinoline derivatives as inhibitors or Rho-kinase
TWI370127B (en)	2012-08-11	Pyrazolylaminopyridine derivatives useful as kinase inhibitors
HK1139390A1 (en)	2010-09-17	Cycloalkylamine substituted isoquinolone derivatives
HK1105592A1 (en)	2008-02-22	Aryl-pyridine derivatives as 1-beta-hsd1 inhibitors
ZA200702394B (en)	2008-11-26	Indozolone derivatives as 11b-HSD1 inhibitors
ZA200806148B (en)	2009-06-24	2-adamantylurea derivatives as selective 11ß-HSD1 inhibitors
IL198247A0 (en)	2009-12-24	Indazole derivatives useful as l-cpt1 inhibitors
ZA200903554B (en)	2010-05-26	Substituted isoquinolines and their use as rho-kinase inhibitors
ZA200903058B (en)	2010-07-28	Heterocyclic derived metalloprotease inhibitors
HK1124068A1 (en)	2009-08-07	2-arylindole derivatives as mpges-1 inhibitors
HK1112918A1 (en)	2008-09-19	Benzofuranyl derivatives as 5-ht6-receptor inhibitors
ZA200801910B (en)	2009-08-26	Isoquinolines derivatives as IGF-IR inhibitors
ZA200706212B (en)	2008-06-25	Pyrazolylaminopyridine derivatives useful as kinase inhibitors